GlobeNewswire by notified

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment

Share
  • Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2
  • Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2
  • These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programme

Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment. A statistically significant and clinically meaningful improvement in overall survival (OS), a secondary endpoint, was observed with adjuvant (post-surgery) Kadcyla® (trastuzumab emtansine) compared to Herceptin® (trastuzumab): at the 7-year landmark OS rates were 89.07% and 84.37% with Kadcyla and Herceptin, respectively (hazard ratio [HR]=0.66, 95% CI: (0.51, 0.87), p-value =0.0027).2 Data also show that the previously reported invasive disease-free survival (primary endpoint) benefit is maintained.2 Kadcyla reduced the risk of disease recurrence or death from any cause by 46% compared to Herceptin (HR=0.54, 95% CI: (0.44, 0.66), p-value <0.0001), strengthening the results of the primary analysis of KATHERINE.2,3 The safety profile of Kadcyla was consistent with previous findings and no new safety signals were identified.2

“We are pleased that Kadcyla could offer people with HER2-positive early breast cancer with a particularly poor prognosis a chance to live longer and without recurrence of their disease,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The ultimate goal of treating early breast cancer is to maximise the chance of cure, and these results signify an important step forward for these patients.”

"Thanks to remarkable advances in diagnostics and treatment, more women are surviving an initial diagnosis of HER2-positive early-stage breast cancer than ever before. However, in those with higher risk disease, recurrence and long-term survival have remained a challenge,” said Prof. Dr. Sibylle Loibl, Chair of the German Breast Group (GBG), Principal Investigator of KATHERINE. “With these new data, Kadcyla is the first targeted therapy to demonstrate a significant survival benefit in people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment."

The KATHERINE study has been conducted in collaboration with the GBG and NSABP Foundation, Inc. Full data are being presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium on Friday 08 December.

Kadcyla is approved in 113 countries and is the standard of care for people with HER2-positive eBC with residual invasive disease following neoadjuvant treatment, based on previous positive results from KATHERINE that showed Kadcyla cut the risk of disease recurrence or death by half versus Herceptin.1,3 Additionally, at three years, 88.3% of people treated with Kadcyla did not have their breast cancer return compared to 77.0% treated with Herceptin, an absolute improvement of 11.3%.3

Breast cancer is the most frequently diagnosed type of cancer, with major societal impact.4 Approximately one in five people with breast cancer will be HER2-positive, a particularly aggressive form of the disease.5 The goal in treating eBC is to provide people with the best chance for a cure.6 While we come closer to this goal with each advance, many people still have disease recurrence in the long-term and more personalised treatment options are needed to reduce this risk and help people live longer.7,8

Kadcyla is also approved for the treatment of people with HER2-positive metastatic breast cancer who previously received trastuzumab and a taxane.

About the KATHERINE study
KATHERINE is an international, multi-centre, two-arm, randomised, open-label, phase III study evaluating the efficacy and safety of Kadcyla versus Herceptin as an adjuvant therapy in people with HER2-positive early-stage breast cancer who have residual invasive disease following neoadjuvant therapy that included Herceptin and taxane-based chemotherapy.9 In KATHERINE, residual invasive disease was defined as the presence of invasive residual disease in tissue samples from breast and/or axillary nodes following neoadjuvant treatment.9 People who have residual invasive disease after neoadjuvant treatment generally have a worse prognosis than those without detectable disease at surgery.10

The primary endpoint of the study is invasive disease-free survival (iDFS) which, in this study, is defined as the time from randomisation free from invasive breast cancer recurrence or death from any cause.9 Secondary endpoints include DFS and overall survival.9

About Kadcyla
Kadcyla is an antibody-drug conjugate (ADC) engineered to deliver potent chemotherapy directly to HER2-positive cancer cells, potentially limiting damage to healthy tissues. It combines two anti-cancer properties joined together by a stable linker: the HER2-targeting properties of trastuzumab (the active ingredient in Herceptin) and the chemotherapy agent DM1.11 Kadcyla is approved for the treatment of people with HER2-positive metastatic breast cancer (as of 2013) and HER2-positive early-stage breast cancer (as of 2019). Roche licenses technology for Kadcyla under an agreement with ImmunoGen, Inc.

About Roche’s medicines for HER2-positive breast cancer
Roche has been leading research into the HER2 pathway for over 30 years and is committed to improving the health, quality of life and survival of people with both early-stage and advanced HER2-positive disease. HER2-positive breast cancer is a particularly aggressive form of the disease that affects approximately 15-20% of patients.5

Roche has developed innovative medicines, including in patient-centric formulations, which have helped transform the treatment of HER2-positive breast cancer: Herceptin® (trastuzumab) in both intravenous and subcutaneous formulations, Perjeta® (pertuzumab), Kadcyla® (trastuzumab emtansine) and PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf).12,13,14 Eligibility for treatment with Roche’s HER2-targeted medicines is determined via a diagnostic test, which identifies people who will likely benefit from these medicines at the onset of their disease.

About Roche in breast cancer
Roche has been advancing breast cancer research for more than 30 years with the goal of helping as many people with the disease as possible. Our medicines, along with companion diagnostic tests, have contributed to bringing breakthrough innovations in HER2-positive and triple-negative breast cancers. As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for all forms of early-stage and advanced breast cancer, including triple-negative and hormone receptor-positive.

Our targeted medicines Herceptin® (trastuzumab), Perjeta® (pertuzumab), PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf), Kadcyla® (trastuzumab emtansine) and Tecentriq® (atezolizumab) are continuing to transform the treatment of early-stage and advanced HER2-positive and triple-negative breast cancers and, through our clinical programmes, we hope to bring new treatment combinations to people with breast cancer, ultimately improving outcomes.12,13,14,15

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Roche data on file.
[2] Loibl S, et al. Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis. Presented at: San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, Texas, USA. Abstract #GS03-12.
[3] von Minckwitz G, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380:617-28.
[4] Arnold M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022;66:15-23.
[5] American Cancer Society. Breast cancer HER2 status [Internet; cited December 2023]. Available from:https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-her2-status.html.
[6] Scharl A, et al. The Right Treatment for the Right Patient - Personalised Treatment of Breast Cancer. Geburtshilfe Frauenheilkd. 2015;75(7):683–91.
[7] Jorge Dino Cossetti R, et al. Comparison of breast cancer recurrence and outcome patterns between patients treated in 1986-1992 and 2004-2008. Journal of Clinical Oncology. 2014;32(15):521.
[8] Dieci MV, et al. Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. Cancer Treat Rev. 2020;88:102064.
[9] Clinical trials.gov. A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) [Internet; cited December 2023]. Available from: https://clinicaltrials.gov/study/NCT01772472.
[10] Cortazar P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-72.
[11] Verma S, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012;367(19):1783-91.
[12] National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines – Version 4.2023 [Internet; cited December 2023]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
[13] Denduluri N, et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO Guideline Update. J Clin Oncol. 2021;39(6):685-93.
[14] Swain S, et al. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22:101-26.
[15] Schmid P, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379:2108-21.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD
Phone: +41 79 407 72 58
Nathalie Altermatt
Phone: +41 79 771 05 25

Simon Goldsborough
Phone: +44 797 32 72 915
Karsten Kleine
Phone: +41 79 461 86 83

Nina Mählitz
Phone: +41 79 327 54 74
Kirti Pandey
Phone: +49 172 6367262

Dr. Rebekka Schnell
Phone: +41 79 205 27 03
Sileia Urech
Phone: +41 79 935 81 48

Roche Investor Relations

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com


Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Prosafe SE: Extraordinary General Meeting completed22.2.2024 09:24:50 CET | Press release

Pursuant to the Notice of 30 January 2024, an Extraordinary General Meeting of Prosafe SE was held today, 22 February 2024. The Extraordinary General Meeting resolved to approve all matters as proposed in the Notice. The minutes from the Extraordinary General Meeting are attached and can be downloaded from http://www.newsweb.no and https://www.prosafe.com Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to https://www.prosafe.com 22 February 2024 Prosafe SE For further information, please contact: Glen Ole Rødland, Chairman of Prosafe SE Phone: +47 907 41 662 Terje Askvig, CEO Phone: +47 952 03 886 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. Attachment EGM 22 February 2024 - Minutes incl attendance and votes

Hitachi Energy invests over 30 million euros to expand transformer operations in Germany22.2.2024 09:23:48 CET | Press release

The expansion and modernization of the power transformer manufacturing facility in Bad Honnef will generate up to 100 new jobs in the region. Set for completion in 2026, the investment expands the company's global footprint and capacity at speed, addressing the accelerating demand for transformers to meet Europe’s energy transition. Zurich, Switzerland, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Hitachi Energy today announced an investment of more than 30 million euros (approx. $32 million) in the expansion and modernization of its power transformer manufacturing facility in Bad Honnef, Germany. Expected to be completed in 2026, the project will generate up to 100 new jobs in the region and address the rising demand for transformers to support Europe's clean energy transition. Operational since 1906, the facility in Bad Honnef is one of Hitachi Energy’s key manufacturing locations in Europe. The factory produces large power transformers, forming critical components of the electrical grid used t

In 2023 cBrain grew revenue by 27% and delivered record high earnings before tax margin (EBT margin) of 34%22.2.2024 09:00:00 CET | Press release

Company Announcement no. 03/2024 In 2023 cBrain grew revenue by 27% and delivered record high earnings before tax margin (EBT margin) of 34% Copenhagen, February 22, 2024 Total revenues grew by +27% to DKK 239m in 2023, up from DKK 188m in 2022. Earnings before tax (EBT) grew by +66% to DKK 81m in 2023, up from DKK 49m in 2022. cBrain (NASDAQ: CBRAIN) thereby reports record high earnings before tax margin (EBT margin) of 34%. cBrain is well on track and executes the 2023-2025 growth plan. The growth plan is based on organic growth, combined with a strong positive cashflow. Fully aligned with the 2023-2025 growth plan, total software revenue, which is based on software licenses and software subscriptions, grew +40%, to DKK 189m in 2023 up from DKK 131m in 2022, while implementation and support services declined by -5% to DKK 50m in 2023, down from DKK 52m in 2022. Software thereby counts for 79% of total revenues in 2023. The results are based on a solid development in Denmark as well a

Aktia Bank Abp: Transaktioner utförda av personer i ledande ställning – Outi Henriksson22.2.2024 09:00:00 CET | Pressemelding

Aktia Bank Abp Börsmeddelande 22.2.2024 kl. 10.00 Aktia Bank Abp: Transaktioner utförda av personer i ledande ställning – Outi Henriksson Den anmälningsskyldiga Namn: Henriksson, Outi Befattning: Ekonomidirektör Emittent: Aktia Bank Abp LEI: 743700GC62JLHFBUND16 Anmälans karaktär: FÖRSTA ANMÄLAN Referensnummer: 53081/5/4 ____________________________________________ Transaktionens datum: 2024-02-21 Handelsplats: NASDAQ HELSINKI LTD (XHEL) Instrument typ: AKTIE ISIN: FI4000058870 Transaktionens karaktär: AVYTTRING Detaljer om transaktionerna (1): Volym: 1500 Enhetspris: 9,1 EUR Aggregerad information om transaktionerna (1): Volym: 1500 Medelpris: 9,1 EUR Aktia Bank Abp Mera information: Mia Smeds, kommunikationsdirektör, tfn 044 546 0379 Distribution: Nasdaq Helsinki Oy Massmedier www.aktia.com Aktia är en finländsk kapitalförvaltare, bank och livförsäkrare som har skapat välstånd och välfärd generation efter generation redan under 200 års tid. Vi tillhandahåller våra kunder digitala tjä

Aktia Bank Plc: Managers’ Transactions – Outi Henriksson22.2.2024 09:00:00 CET | Press release

Aktia Bank Plc Stock Exchange Release 22 February 2024 at 10.00 a.m. Aktia Bank Plc: Managers’ Transactions – Outi Henriksson Person subject to the notification requirement Name: Henriksson, Outi Position: Chief Financial Officer Issuer: Aktia Bank plc LEI: 743700GC62JLHFBUND16 Notification type: INITIAL NOTIFICATION Reference number: 53081/5/4 ____________________________________________ Transaction date: 2024-02-21 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000058870 Nature of the transaction: DISPOSAL Transaction details (1): Volume: 1500 Unit price: 9.1 EUR Aggregated transactions (1): Volume: 1500 Volume weighted average price: 9.1 EUR Aktia Bank Plc Further information: Mia Smeds, Communications Director, tel. +358 44 546 0379 Distribution: Nasdaq Helsinki Ltd Mass media www.aktia.com Aktia is a Finnish asset manager, bank and life insurer that has been creating wealth and wellbeing from one generation to the next for 200 years. We serve our customers in di

HiddenA line styled icon from Orion Icon Library.Eye